Cryoport (CYRX) Stock
Specialized temperature controlled logistics provider for life sciences. Here's the price, business snapshot, and what's worth knowing about Cryoport in October 2026.
Cryoport, Inc. specialises in cryogenic logistics and temperature-controlled transport for the life‑sciences sector, supporting cell and gene therapies, biologics, vaccines and reproductive materials. The company provides specialised containers, monitoring technology and global shipping services designed to maintain ultra-low temperatures and regulatory traceability. Investors should note Cryoport’s growth is linked to the broader adoption of complex biologics, partnerships with biopharma and geographic expansion, but it faces execution, capital and competitive risks typical of a specialised logistics provider. Revenues can be recurring from contractual relationships, yet margins and cash flows depend on scale, utilisation and operational reliability. Regulatory oversight, supply-chain disruption and technological change are important considerations. This summary is for general educational purposes only and not personalised investment advice; values can fall as well as rise and prospective investors should assess suitability against their own circumstances.
Cryoport (CYRX) Stock Forecast
Analyst price target, next 12 months
$18.20
+4.4% vs today's $17.43
Price range over the last 12 months
Close to its 12-month high
Analysts covering Cryoport have a consensus 12-month target of $18.20, above the current price of $17.43.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Cryoport's stock with a target price of $18.2, indicating potential growth.
Financial Health
Cryoport Inc. shows solid revenue and cash flow, which indicates strong business performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Biologics cold chain
Demand for cell and gene therapies supports long‑term market growth, though commercialisation timelines and adoption can vary and affect revenue.
Global network expansion
Partnerships and international hubs can drive recurring revenues and scale benefits, but regulatory complexity and logistics risks remain.
Execution and competition
Scalability and operational reliability are critical; competition and capital needs can pressure margins, underscoring execution risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
